Celebration of Humanity
Our commitment is to make a meaningful impact on people’s lives benefiting from genetic science through preventive and personalized wellness
Although all individuals look and think differently, live different lifestyles and speak different languages, 99% of our genetic makeup is common across all humans. The diversity between us comes from the remaining 1%. Our mission is to embrace this 1%, to use genetic analysis to encourage creating a healthy society that celebrates diversity.
Our core genetic business is based on our Vision that in the next 10-20 years and during the 21st Century, the rise of Bio-technology, Genomics and Machine Learning will become a disruptive force in how we lead our lives. With this technology combined, the human brain power will be overpowered with a more powerful information source that could ultimately change the way we think, decide about our health, our profession and how we communicate since the power of computing will be able to better predict the outcome of our choices.
When computing power has advanced intelligence and consistency than our human brain and the technology is readily made available to alter the course of genetic destiny, we need to be responsible while wary of the setbacks that can occur due to the rising technological information age at the same time.
While technologies such as gene therapy or gene editing is entirely applaudable to help the current sick and suffering genetic disorders, imagine what society would be if genes could be altered to our personal preference. Such ethically disruptive decision could erode to a higher wealth distribution gap affecting economic opportunity not only on a personal scale but on a country scale. Within each country, those that do not have access to genetic technology could be suppressed to a robotic function in society. While these may be disruptive ideologies that seem to not be approachable in our current time, the truth is that the technology and information is already becoming available.
Based on our vision, our Corporate Philosophy is identified through 4 key areas to address Ethics, Social Responsibility and Celebration of Humanity as common goals to address the issues and solutions for the ever-expanding use of genetic information and technology without disturbing innovation and scientific advancements:
3. Corporate Governance
Compassion: The word Compassion in Japanese is called “Jihi. Jihi is also commonly used in Buddhist teachings as a spirituality of enlightenment. The first syllable, “ji” signifies love that grants blessings and respect and personal freedom from caring for others. The Second syllable, “hi,” is benevolence that seeks to rescue people from suffering. Compassion, under Buddhist teachings therefore means to help people rid themselves from suffering and giving them peace. At Genesis Healthcare, Compassion is the most important Philosophy that we adhere to and speak every day. Every decision we make is based on Compassion to help others and society.
On this notion, we connect to our second Corporate Philosophy, “Cooperation. “ Humans, throughout our history, have also sought comfort in a band or group of common people with similar culture, history, or ethnic background. It is human nature to feel uncomfortable when there is a different member in a small band of people. However, in our global society, we must “cooperate” and learn to understand and respect our neighbors. At Genesis Healthcare, our employees come from 5 continents, over 10 countries and comprise a widely diversified melting pot from different backgrounds from around the world, commanding a level of communication and cooperation unlike none seen in Japanese companies. We are able to cooperate because our treatment toward each other is based on Compassion and Cooperation.
Corporate Governance is about responsibility to society. As the leader and pioneer in Genetics in Japan, we constantly question the integrity of our actions at all levels including the types of genetic tests that we offer to proactively engaging ourselves in dialogues with Regulators in formulating guidelines that benefit society, customers and patients. It is our view that ethics is just a word on paper unless it is practiced and put into action.
And finally, Genesis Healthcare encourages “Change.” While modern medicine has proven to be effective in many ways, it also has its many challenges including side effects or high costs. With our challenge towards advancement of gene therapy or pursuing new genetic technologies to help those that are suffering, Change is a driver of growth at Genesis Healthcare to be in the forefront the genetic industry. We are constantly pushing ourselves to find the best solution for all stakeholders that resonate with compassion and Corporate Governance with respect towards modern medicine. Perhaps, it is worth to note that the only constant within Genesis Healthcare is its ability to Change and to promote change.
At Genesis Healthcare, we uphold a unique and innovative HR initiative which focuses on recruiting and retaining talent from those from all backgrounds and offer placement in areas without much experience. The reason is, we value ambition for newcomers to pursue new career areas.
We also do not call our employees “Employees” as is common with most companies. Our employees are referred to as either “Innovators,” “Creators,” “Disruptors,” or “Educators.” We focus on hiring those that can demonstrate their unique talent and potential despite their current, former positions or education.
Project Groups across members of different divisions are typically formed with those from different background to offer fruitful discussions and to bring out the best of delivering the best products, tests and services with the vision in mind. As a result, Genesis may lack organization or structure from within. But, with different mindsets constantly seeking Innovation, Creation, Disruption or Education always at work, it will feel like you are travelling into the future as well. We hope you will choose Genesis Healthcare and become part of the future of genetic science.
|Company Name||Genesis Healthcare Co.|
|Incorporation||March 1, 2004|
|Capital||3,350Million Yen (Including Capital Reserve) As of October 2019|
|Business Licence||Approval for Third-Class Production and Distribution of Medical Devices|
|Registrated Industry||Medical Device Manufacturing
Registered Public Health Laboratory
- Hematological Testing (Germline Gene Testing, Somatic Gene Testing)
|Member Organizations||CPIGI (Council for Protection of Individual Genetic Information)
Japan Bioindustry Association
|Location (Headquarters)||Yebisu Garden Place Tower 15F/26F 4-20-3 Ebisu, Shibuya-ku, Tokyo, JAPAN, 150-6026 (Main Reception: 15F)
TEL 03-5422-8506 FAX 03-5422-8526
|Laboratory||Yebisu Garden Place Tower 26F 4-20-3 Ebisu, Shibuya-ku, Tokyo, JAPAN, 150-6026|
Genesis Healthcare Asia Pte. Ltd.
20 Cecil St #23-05 PLUS Singapore 049705
2F., No.394, Sec. 1, Keelung Rd. , Xinyi Dist., Taipei City 110, Taiwan (R.O.C.)
|Chairman of the Board||David Baran (Founder)|
|President||Dr. Iri Sato Baran (Founder)|
|External Director||Dr. Kozo Denpo (DHC Corporation)|
|External Director||Tetsu Kayama|
|External Director||Kazuhiko Shibata|
|External Director||Hiroshi Mikitani (Rakuten, Inc.)|
|External Director||Matthew J. Burlage|
|Special Advisor||Toshiharu Furukawa M.D., M.B.A., Ph.D., Attorney|
|Advisor||Nobuaki Tanaka M.D., Ph.D.|
|Medical Science Advisor||Shohei Matsuzaki M.D., Ph.D., Professor Emeritus Tokai University|
|2004.03||Founded by David Baran and Dr. Iri Sato-Baran.|
|2004.09||Commenced gene therapy research & development.|
|2005.03||Started genetic testing services to medical and academic institutions.|
|2008.06||Launched consumer test service [GeneLife] to partners.|
|2010.09||Obtained Japan patent for gene therapy.|
|2011.03||Surpassed 100,000 kits sold.|
|2011.04||Established Genesis Institutes for Genetic Research to expand in-house research.|
|2011.08||Obtained international patent for gene therapy.|
|2012.02||Commenced online/E-commerce services.|
|2012.05||Launched GeneLife, our direct-to-consumer (DTC) brand, targeting Japanese and Asian customers.|
|2012.06||Surpassed 200,000 kits sold.
Started DNA banking services.
|2012.12||Launched GeneLife2012, the first microarray-based DTC product.
Obtained Medical Device Manufacturing license and Medical Device Distribution license.
|2013.04||GeneLife online services and apps became available on smartphones.|
|2013.06||Surpassed 300,000 kits sold.|
|2013.09||Start of GIGR (Cancer / GWAS) services, a testing kit for medical facilities.|
|2013.12||Launched GeneLife Haplo.|
|2014.03||Launched GeneLife Zero, a comprehensive DTC kit commemorating Genesis Healthcare’s 10-year Anniversary|
|2014.05||Launched the “AR” genetic testing kit.|
|2014.09||Launched the “GeneLifeNEO” genetic testing kit.|
|2014.10||Launched the “Myself” genetic testing kit.
Affiliation with Genesis Medical Clinic Roppongi, the first genetic test-focused private clinic in Japan.
|2015.06||Surpassed 400,000 kits sold.|
|2015.07||Third Party allotment of new shares with approximately 620 million yen underwritten by MITSUI & CO., LTD. and Founders Fund.
Commenced the “Tezuka Osamu” Genetic Analysis Project, a collaboration with the famous Manga artist of the same name.
Launched the “Genesis” genetic testing kit.
Launched television commercials on major networks in Japan.
|2015.08||Launch of BRCA1/2 Familial Breast Cancer test as a screening test to medical institutions in Japan.|
|2015.11||Expansion of consumer genetic testing services to Asian countries.|
|2016.06||“GeneLife” was granted accreditation by ‘CPIGI (Council for Protection of Individual Genetic Information)’.|
|2016.10||Surpassed 500,000 kits sold.|
|2017.04||Office and laboratory move to Yebisu Garden Place.|
|2017.08||Third Party allotment of new shares with approximately 1.4 billion yen underwritten by Rakuten, Inc..|
|2017.09||Launched “GeneLife Genesis 2.0”, which examines about 1500 genes to determine over 360 traits.|
|2017.10||Launched a genetic testing membership service, “GeneLife Premium”.|
|2018.02||Reached third-party equity allocation agreement with Rakuten, Inc. and Omron Healthcare Co., Ltd. with an amount of 1.65 Billion JPN Yen.|
|2018.06||Surpassed the threshold of 600,000 total number of analyses conducted|
|2018.10||Launched “Genesis Asia 1000” Project, a project aiming to assemble a database specialized in Japanese and Asian populations.
Introduced whole genome sequencing services.
|2019.03||Genesis Healthcare’s 15-year Anniversary
Surpassed 700,000 kits sold.
|2019.04||Launched “GenesisGaia”, a genomic marketplace based on the Sharing Economy model.|
|2019.11||Surpassed 800,000 kits sold.|